Shabir Madhi to Antibodies, Neutralizing
This is a "connection" page, showing publications Shabir Madhi has written about Antibodies, Neutralizing.
Connection Strength
4,243
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
Score: 0,811
-
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
Score: 0,614
-
Impaired Transplacental Transfer of Respiratory Syncytial Virus-neutralizing Antibodies in Human Immunodeficiency Virus-infected Versus -uninfected Pregnant Women. Clin Infect Dis. 2019 06 18; 69(1):151-154.
Score: 0,545
-
Neutralization and hemagglutination-inhibition antibodies following influenza vaccination of HIV-infected and HIV-uninfected pregnant women. PLoS One. 2018; 13(12):e0210124.
Score: 0,527
-
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
Score: 0,196
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
Score: 0,181
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,172
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0,158
-
Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants. J Pediatric Infect Dis Soc. 2020 Jul 13; 9(3):349-356.
Score: 0,147
-
Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants. Expert Rev Vaccines. 2019 07; 18(7):751-754.
Score: 0,136
-
Prevaccination Rotavirus Serum IgG and IgA Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants. Clin Infect Dis. 2016 Jan 15; 62(2):157-65.
Score: 0,105
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
Score: 0,050
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
Score: 0,050
-
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
Score: 0,049
-
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study. Sci Rep. 2024 03 04; 14(1):5365.
Score: 0,047
-
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
Score: 0,045
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
Score: 0,045
-
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).
Score: 0,044
-
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. Sci Rep. 2023 01 21; 13(1):1222.
Score: 0,044
-
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):501-517.
Score: 0,043
-
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
Score: 0,041
-
Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine. 2021 09 15; 39(39):5513-5523.
Score: 0,040
-
In Utero Human Cytomegalovirus Infection Is Associated With Increased Levels of Putatively Protective Maternal Antibodies in Nonprimary Infection: Evidence for Boosting but Not Protection. Clin Infect Dis. 2021 08 16; 73(4):e981-e987.
Score: 0,040
-
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
Score: 0,039
-
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1899-1909.
Score: 0,039
-
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020 07; 20(7):851-863.
Score: 0,036